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http://dx.doi.org/10.1016/j.immuni.2012.06.004Brown and colleagues (Brown et al., 2012)
contend that in our recent analyses on
the role of mast cells in antibody- and
T cell-mediated autoimmunity (Feyera-
bend et al., 2011), we have ignored
‘‘overwhelming evidence supporting the
diverse functions of mast cells.’’ They
also claim that we have induced experi-
mental autoimmune encephalomyelitis
(EAE) in our Kit-independent mast
cell-deficient mouse (Cpa3Cre/+) in a way
that ‘‘probably obscures mast cell con-
tributions.’’ As delineated below, the
evidence for widespread immunological
functions of mast cells beyond IgE-driven
responses is not overwhelming but has,
for the most part, relied on a single experi-
mental system, i.e., the use of Kit mutant
mice. These mutants not only lack mast
cells but alsosuffer frommultipleadditional
defects in cells inside and outside of the
immune system. As further argued below,
the long-standing mast cell reconstitution
assay in Kit mutants is not necessarily
a faithful indicator of mast cells’ in vivo
functions. Regarding EAE, the original
claim by Brown et al. that ‘‘mast cells are
essential for early onset and severe
disease’’ (Secor et al., 2000) has remained
controversial. In fact, before publication
of our data showing susceptibility of
Kit-independent mast cell-deficient
Cpa3Cre/+ mice to EAE, even experiments
in mast cell-deficient Kit mutants, the
model originally used, yielded conflicting
results. One study subjected two different
Kit mutants (KitW/Wv and KitW-Sh/W-Sh),
both of which lack mast cells, to EAE, and
performed the experiments in different
institutions to account for potential labora-
tory-specific or environmental conditions.
Both mast cell-deficient strains were
susceptible to disease (Bennett et al.,
2009). Further studies showed that experi-
ments in KitW/Wv mice can be ‘‘tuned’’
toward either inhibition or promotion of
EAE disease outcome (Piconese et al.,
2011). Notably, both results have been ob-
tained in the absence of mast cells and are
hence unrelated to mast cells. Moreover,KitW-Sh/W-Sh mice, despite their mast cell
deficiency, developed even earlier and
more severe clinical and pathological
disease with extensive demyelination and
inflammation in the CNS (Li et al., 2011; Pi-
coneseet al., 2011).Collectively, there is all
but a clear picture on EAE outcome in Kit
mutant mice. It remains therefore elusive
on what grounds the reiterated claim of
Brown and colleagues stands that ‘‘it is
firmly established that MCs regulate EAE’’
(Sayed et al., 2011) and that rheumatoid
arthritis andmultiple sclerosis are diseases
previously demonstrated to be mast cell
dependent (Brown et al., 2012), when, in
fact, models for these diseases were
studied only in Kit-deficient mice. If mast
cells were key cellular modulators in EAE,
one might expect to find ameliorated
pathology in the absence of mast cells as
a common denominator across all of these
experiments. This is not the case. For data
to become generally accepted, indepen-
dent confirmation by other laboratories,
and in as many independent experimental
systems possible, is mandatory. In view
of the fact that the results in Kit mutant
mice are highly variable, and given the
pleiotropic defects caused by Kit muta-
tions in several organ systems, it seemed
justified to subject a Kit-independent
mast cell-deficient mouse to models of
autoimmunity. Not only did we not find
a role for mast cells in EAE in this strain,
but we also did not confirm a phenotype
of decreased susceptibility of KitW/Wv
mice (WB3C57BL/6 background) (Feyer-
abend et al., 2011). Based on these data,
we considered in our manuscript a major
role for mast cells in MOG-induced EAE
induction or progression unlikely. In
contrast tomore robust earlier statements,
Brownetal. (2012)nowpropose that ‘‘mast
cells, by definition, can play only a modi-
fying role at best.’’ The connotation by
Brown et al. (2012) that our experimental
approach to induce EAE is in any way
fundamentally different from the standard
protocol, including the one originally used
by the Brown laboratory, is not correct.ImmunityExperimental conditions (immunization
protocols,MOGpeptide, dose of pertussis
toxin, and adjuvant) are all very similar in
most studies, including ours, addressing
EAE in mast cell-deficient mice. One could
argue that it is possible that mast cells can
modifyEAE responsesat one level of inten-
sity but have redundant functions in
a stronger response. However, compared
to the original protocol used by Brown
et al. (Secor et al., 2000), our immunization
protocol is if anything milder, and it there-
fore appears misleading to claim that
‘‘overwhelming inflammation’’ ‘‘masks the
mast cell contribution.’’ In our view, it is
plausible to considerKit as themajor factor
influencing mast cell in vivo experiments
before dismissing new data based on Kit-
independent models as improper applica-
tions of ‘‘well-validated approaches.’’ This
view is supported not only by our work on
autoimmunity (Feyerabend et al., 2011)
but also by recent studies on contact
hypersensitivity (Dudeck et al., 2011),
which yielded conflicting results
comparing Kit mutant mast cell-deficient
and Kit-independent mast cell-deficient
mice.
Brown et al. (2012) also defend the
concept of the ‘‘multifunctional mast
cell’’ with ‘‘contributions to protective
immunity in viral and bacterial infections,
in maintaining homeostasis and immu-
nologic tolerance, and in exacerbating
pathologic inflammation associated with
cancer, heart disease, and autoimmu-
nity.’’ It should be noted again in this
global context that in vivo analyses of
mast cell functions have until recently
almost entirely rested on the use of Kit
mutants. The selective reconstitution of
Kit mutants with cultured mast cells has
been the standard assay to test mast
cell functions in Kit mutants (Nakano
et al., 1985). However, given that recent
experiments revealed fundamental
discrepancies comparing Kit-dependent
(without and after mast cell reconstitution)
and Kit-independent mouse models of
mast cell deficiency, it is now obvious36, June 29, 2012 ª2012 Elsevier Inc. 893
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can generate misleading results. Mast
cell-specific deletion of the gene encod-
ing IL-10 in Mcpt5-Cre mice failed to
reveal a role for mast cell-derived IL-10
in the regulation of contact allergy (Du-
deck et al., 2011). Such a role had been
reported based on mast cell reconstitu-
tion of Kit mutants (discussed in Dudeck
et al., 2011). In the case of the auto-anti-
body-driven arthritis in the K/BxN model,
we confirmed the resistance of Kit
mutants (discussed in Feyerabend et al.,
2011); however, mast cell-deficient mice
wild-type for Kit were susceptible to the
K/BxN arthritis. In the case of EAE, we
found no phenotype in either Kit-deficient
or Kit-proficient mice lacking mast cells.
Hence, in these instances conclusions
based on Kit mutants did not hold up
when tested in mast cell-deficient mice
wild-type for Kit. Mast cell reconstitution
experiments were included in our manu-
script in response to reviewers’ requests,
although we are not convinced by this
approach. Also, it is not paradoxical but
logical not to test the influence of mast
cell reconstitution in a disease model
that does not show a defect in the
absence of mast cells, e.g., as in EAE.
Despite their lack of mast cells, the
immune system of Cpa3Cre/+ mice was894 Immunity 36, June 29, 2012 ª2012 Elsevindistinguishable from mast cell-bearing
mice, except for the full defect in anaphy-
laxis and a reduction in basophils, which
are, however, also reduced in KitW/Wv
mice (Feyerabend et al., 2011; Mancardi
et al., 2011). It is obvious that mast cell-
related immune defects in Cpa3Cre/+
mice beyond allergic disease may not
manifest until mice are challenged in other
ways. Even in the case of parasites, the
statement by Brown et al. (2012) that
mast cells are ‘‘the major effector cells in
responses to helminth infection’’ is an
exaggeration. Although we indeed
showed that mast cells failed to expand
in the intestines of Cpa3Cre/+ mice upon
N. brasiliensis infection (Feyerabend
et al., 2011), we did not state that this
expansion is protective, which, in fact, it
is not (unpublished).
In summary, recent developments in
this field have provided new opportuni-
ties to readdress the role of mast cells
in immunology independent of Kit. The
use of Kit mutants appeared plausible,
but these mutants, and the mast cell
reconstitution approach, always bore
intrinsic caveats. We hope that the
quest for new genetic tools to study
mast cell biology in vivo shall eventually
convince the mast cells to yield their
secrets.ier Inc.REFERENCES
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